Physician profile
Brittany B Albright
NPI 1265796726
$691,017.92
in general payments reported to CMS, 2019-2025
40 companies · $458K in 2025
The $458K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,123 · 2020: $1,101 · 2021: $1,813 · 2022: $1,831 · 2023: $122K · 2024: $105K · 2025: $458K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $384K · Honoraria: $123K · Travel and Lodging: $102K · Consulting Fee: $50K · Food and Beverage: $26K · Education: $88.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $384,048.50 |
| Honoraria | $122,808.00 |
| Travel and Lodging | $102,296.84 |
| Consulting Fee | $49,775.50 |
| Food and Beverage | $26,133.02 |
| Education | $88.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $339,080.77 | 2019-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Axsome Therapeutics, INC. | $143,239.51 | 2022-2025 | Auvelity, Sunosi |
| Abbvie INC. | $68,959.55 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| E.R. Squibb & Sons, L.L.C. | $62,358.17 | 2024-2025 | Cobenfy |
| Alkermes, INC. | $56,987.88 | 2022-2025 | Lybalvi, Aristada |
| Eli Lilly and Company | $9,703.43 | 2025 | |
| Neurocrine Biosciences, INC. | $2,966.19 | 2021-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $1,438.53 | 2019-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $870.43 | 2019-2025 | Trintellix |
| Corium, LLC | $679.96 | 2022-2025 | Azstarys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $629.24 | 2020-2025 | Caplyta |
| Lundbeck LLC | $615.01 | 2019-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $454.70 | 2020-2025 | Fanapt, Hetlioz |
| Neos Therapeutics, Lp | $378.75 | 2021-2024 | Adzenys Xr-Odt |
| Bausch Health US, LLC | $311.67 | 2019-2024 | Aplenzin |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brittany Albright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.